Brandon G. Smaglo, MD, FACP

Brandon G. Smaglo, MD, FACP, is an associate professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Articles by Brandon G. Smaglo, MD, FACP

Brandon G. Smaglo, MD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Dr Smaglo on Selecting Between Frontline Chemotherapy Regimens for Pancreatic Cancer

ByBrandon G. Smaglo, MD, FACP

February 28th 2025

Brandon G. Smaglo, MD, FACP, discusses considerations for choosing between frontline chemotherapy-based regimens for patients with pancreatic cancer.

Dr Smaglo on the Evolution of RAS-Targeted Therapies for Pancreatic Cancer

ByBrandon G. Smaglo, MD, FACP

November 21st 2024

Brandon G. Smaglo, MD, FACP, discusses the ongoing research with RAS-targeted therapies for pancreatic cancer.

Dr. Smaglo on the Future of Immunotherapy in Gastric Cancer

ByBrandon G. Smaglo, MD, FACP

June 15th 2020

Brandon G. Smaglo, MD, FACP, discusses the future of immunotherapy in gastric cancer.

Dr. Smaglo on the Role of Immunotherapy in Advanced Gastric Cancer

ByBrandon G. Smaglo, MD, FACP

May 27th 2020

Brandon G. Smaglo, MD, FACP, discusses the role of immunotherapy in advanced gastric cancer.

Dr. Smaglo on Novel Therapies in Advanced Gastric Cancer

ByBrandon G. Smaglo, MD, FACP

May 12th 2020

Brandon G. Smaglo, MD, FACP, discusses novel therapies in advanced gastric cancer.

Dr. Smaglo on Novel Therapies in Advanced Gastric Cancer

ByBrandon G. Smaglo, MD, FACP

May 11th 2020

Brandon G. Smaglo, MD, FACP, discusses novel therapies in advanced gastric cancer.

Dr. Smaglo Discusses the FDA Approval of TAS-102 for Gastric/GEJ Cancer

ByBrandon G. Smaglo, MD, FACP

February 26th 2019

Brandon G. Smaglo, MD, FACP, assistant professor of internal medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the FDA approval of TAS-102 (trifluridine/tipiracil; Lonsurf) in gastric/gastroesophageal junction (GEJ) adenocarcinoma.